<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00302419</url>
  </required_header>
  <id_info>
    <org_study_id>5737</org_study_id>
    <nct_id>NCT00302419</nct_id>
  </id_info>
  <brief_title>Effect of Complementary Intracoronary Streptokinase Administration Immediately After Primary Percutaneous Coronary Intervention on Microvascular Perfusion and Late Term Infarct Size in Patients With Acute Myocardial Infarction</brief_title>
  <official_title>Effect of Complementary Intracoronary Streptokinase Administration Immediately After Primary Percutaneous Coronary Intervention on Microvascular Perfusion and Late Term Infarct Size in Patients With Acute Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istanbul University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istanbul University</source>
  <brief_summary>
    <textblock>
      The investigators hypothesized that complementary intracoronary streptokinase administration&#xD;
      to primary percutaneous intervention in patients with acute myocardial infarction may provide&#xD;
      further improvement in myocardial perfusion by dissolving microvascular thrombus [in situ&#xD;
      formed or embolized from proximal site (spontaneous or following PCI)] and fibrin.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Mechanical reperfusion for acute myocardial infarction (AMI) targets optimal&#xD;
      revascularization of the epicardial artery but also aims at improved myocardial salvage. The&#xD;
      goal of reperfusion therapies has shifted to include reperfusion downstream at the level of&#xD;
      capillary bed, and it might be more appropriate that the hypothesis now be termed &quot;the time&#xD;
      dependent open artery and open microvascular hypothesis.&quot; Failure to achieve myocardial&#xD;
      reperfusion despite the presence of a patent coronary artery has been termed the &quot;no-reflow&quot;&#xD;
      phenomenon and attributed to microvascular dysfunction. It has become apparent that clinical&#xD;
      outcomes are not only associated with patency of the epicardial artery, but also with patency&#xD;
      of the microcirculation. Persistent impairment of microcirculation is associated with poor&#xD;
      clinical outcome. Complete reperfusion in AMI settings necessitates reopening of the all&#xD;
      consecutive vascular compartments all the way through the coronary circulation. But,&#xD;
      embolization following percutaneous coronary intervention (PCI) and in situ microthrombi&#xD;
      generation at the microvascular level makes this goal difficult to achieve. For this reason,&#xD;
      mechanical intervention to the epicardial coronary artery with or without using distal&#xD;
      protection wouldn't be enough to achieve ideal reperfusion at the ultimate (microvascular)&#xD;
      level. At this point, it has become more evident that we need to develop more competent and&#xD;
      feasible reperfusion strategies which can help us to achieve reperfusion as complete as&#xD;
      possible at all levels.&#xD;
&#xD;
      Hypothesis:&#xD;
&#xD;
      Complementary intracoronary streptokinase administration to primary PCI may provide further&#xD;
      improvement in myocardial perfusion by dissolving microvascular thrombus [in situ formed or&#xD;
      embolized from proximal site (spontaneous or following PCI)] and fibrin. Improvement in&#xD;
      microvascular perfusion may translate into reduction in infarct size and improvement in left&#xD;
      ventricular function at long term.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2004</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">February 2006</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary end points defined as the indices of the microvascular perfusion which is going to be assessed on day 2 (48 hours after the primary PCI)and infarct size at 6 months.</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Index of microvascular resistance,</measure>
    <time_frame>48 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Coronary flow reserve</measure>
    <time_frame>48 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Left ventricular infarct size by SPECT at six months.</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reinfarction</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major bleeding</measure>
    <time_frame>during hospitalization</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">95</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Following standard primary percutaneous coronary intervention for ST elevation acute myocardial infarction 250.000 U intracoronary Streptokinase will be given</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard percutaneous coronary intervention for ST elevation myocardial infarction will be performed</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intracoronary infusion,</intervention_name>
    <description>streptokinase, 250,000 units</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Streptase</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>primary percutaneous coronary angioplasty</intervention_name>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Continuous chest pain that lasted &gt; 30 minutes within the preceding 12 hours&#xD;
&#xD;
          -  ST-segment elevation of at least 1 mm in 2 contiguous leads on the 12 leads ECG&#xD;
&#xD;
          -  Infarct related artery (IRA) occlusion (TIMI grade 0) at the angiography&#xD;
&#xD;
          -  Angiographically detected culprit coronary artery lesion deemed suitable for PCI&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindications to streptokinase, tirofiban, aspirin, clopidogrel, or heparin&#xD;
&#xD;
          -  Culprit lesion in saphenous vein graft&#xD;
&#xD;
          -  TIMI grade II-III flow in IRA&#xD;
&#xD;
          -  Additional epicardial stenosis in the IRA distal to stented segment (significant or&#xD;
             insignificant)&#xD;
&#xD;
          -  Presence of left bundle branch block&#xD;
&#xD;
          -  History of prior MI&#xD;
&#xD;
          -  Mechanical ventilation or inotropic support&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Murat Sezer, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Istanbul University, Istanbul School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sabahattin Umman, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istanbul University, Istanbul School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Taner Goren, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>Istanbul University, Istanbul School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Huseyin Oflaz, Assoc.Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>Istanbul University, Istanbul School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Irem Okcular, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Istanbul University, Istanbul School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>YÄ±lmaz Nisanci, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>Istanbul University, Istanbul School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Berrin Umman, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>Istanbul University, Istanbul School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ahmet K Bilge, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Istanbul University, Istanbul School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mehmet Meric, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>Istanbul University, Istanbul School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Istanbul University, Istanbul School of Medicine, Department of Cardiology</name>
      <address>
        <city>Istanbul</city>
        <zip>34290</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>July 2008</verification_date>
  <study_first_submitted>March 13, 2006</study_first_submitted>
  <study_first_submitted_qc>March 13, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 14, 2006</study_first_posted>
  <last_update_submitted>July 30, 2008</last_update_submitted>
  <last_update_submitted_qc>July 30, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 1, 2008</last_update_posted>
  <responsible_party>
    <organization>Istanbul University Faculty of Medicine</organization>
  </responsible_party>
  <keyword>Acute myocardial infarction</keyword>
  <keyword>primary angioplasty</keyword>
  <keyword>streptokinase</keyword>
  <keyword>microvasculature</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Streptokinase</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

